Lev’s Hereditary Angioedema Agent Cinryze Could Reach Market In Early 2008
This article was originally published in Pharmaceutical Approvals Monthly
The latest "ultra-orphan" compound to reach FDA is Lev Pharmaceuticals’ C1-esterase inhibitor Cinryze for the acute treatment of hereditary angioedema. Lev submitted the biologic July 31.
You may also be interested in...
Lev Pharmaceuticals received a "complete response" letter from FDA on its BLA for the C1-esterase inhibitor Cinryze for hereditary angioedema, giving German drug maker Jerini an opportunity to be first to market with a treatment for the orphan disease
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.